HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ — Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as “Zylox-Tonbridge” or the “Company”) announced that its ZENFlow Tiger The™ LD PTA Dilatation Catheter (hereinafter referred to as “Genflo Tiger™”), a product independently developed by the company, has received marketing approval from ANVISA. The company expects the launch of this newly approved product to provide a solid start to its business development in the South American market.
ZENFlow Tiger™ has many outstanding features. Its braided delivery shaft provides excellent pushability and kink resistance, while low-temperature molding technology ensures excellent non-compliance. With its unique tapered tip and short shoulder design, the ZenFlo Tiger™ can facilitate access to complex wounds and maximize the protection of normal blood vessels. Additionally, a coaxial catheter shaft design allows the ZENFlow Tiger™ to be rapidly inflated and deflated, and it is available in a wide range of sizes for different clinical needs.
The company also expects ZENFlow Tiger™ to show benefit in the treatment of various vascular diseases, such as iliac vein compression syndrome, Budd-Chiari syndrome and other peripheral vascular occlusions. The company expects to see improved treatment efficacy when this product is used appropriately with mechanical thrombectomy devices and peripheral stents.
Driven by greater awareness of treatment options in the aging population and the development of interventional techniques, the market for peripheral vascular interventional devices is growing rapidly in recent years. By introducing ZENFlow Tiger™ to the Brazilian market, the company hopes to provide local patients with high-quality products and comprehensive solutions, while continuing to grow and succeed in its international business.
In 2023, Zylox-Tonbridge has made great progress in overseas markets. The company generated revenue of 6.23 million yuan, showing a year-on-year increase of 128.7% during the first half of this year. As of the end of June, the company’s products have been successfully commercialized in several developed overseas markets. Leveraging on its strong R&D capabilities and advanced manufacturing platforms, the company also provided OEM services to local brands in some emerging markets.
Looking ahead, Zylox-Tonbridge plans to continue investing in international markets, providing more innovative medical device products and solutions to patients around the world.
About Zylox-Tonbridge:
Zylox-Tonbridge is one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China. The company was founded in 2012 and is headquartered in Hangzhou, China.
As an integrated medical device company supported by our in-house R&D and manufacturing capabilities, proprietary technology platforms and commercialization capabilities, we strive to provide high-quality and affordable medical devices and services to patients, so that everyone to have access to high-quality Quality life brought to you by advanced medical technology.
For more information, please visit our official website: www.zyloxtb.com
View original content: https://www.prnewswire.com/news-releases/zylox-tonbridges-zenflow-tiger-ld-pta-dilatation-catheter-receives-anvisa-marketing-approval-301914385.html
SOURCE Xylox-Tonbridge
Source: www.bing.com
